Disclaimer: This document provides general medical information and is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment and consider individual patient circumstances, local guidelines, and the latest evidence when making patient care decisions.

Hep B

Overview

• Definition: Hepatitis B (Hep B) is a liver infection caused by the Hepatitis B virus (HBV), a hepadnavirus. Infection can be acute, lasting less than six months, or chronic, persisting for six months or longer. Chronic HBV infection can lead to serious liver damage, including cirrhosis, liver failure, and hepatocellular carcinoma (HCC).
• Epidemiology:
  • Global Burden: Globally, over 290 million people live with chronic HBV infection. It is a major cause of liver disease and liver-related mortality worldwide, contributing to approximately 820,000 deaths annually.
  • Prevalence: Highest prevalence is in sub-Saharan Africa and East Asia (often >8% of the adult population), intermediate in parts of Eastern Europe, the Middle East, and South Asia (2-7%), and low in Western Europe, Australia, and the Americas (<2%).
  • Transmission: Primarily transmitted through blood and body fluids.
    • Perinatal: Most common mode globally, mother-to-child transmission at birth.
    • Sexual: Unprotected sexual contact with an infected person.
    • Parenteral: Sharing needles for injection drug use, unsterile medical/dental procedures, accidental needle sticks, tattooing, piercing, unvetted blood transfusions.
    • Household: Close contact with an HBV-infected person, though less common than other routes.
  • Demographics: Risk is higher in individuals born in HBV-endemic regions, intravenous drug users, men who have sex with men (MSM), healthcare workers, incarcerated individuals, and those with multiple sexual partners.
• Classification:
  • Acute Hepatitis B: Self-limiting infection, typically lasting <6 months. Characterized by the presence of HBsAg and IgM anti-HBc.
  • Chronic Hepatitis B (CHB): Persistence of HBsAg for ≥6 months. CHB is further categorized into phases based on the interplay between HBV replication, host immune response, and liver damage. These phases are dynamic and a patient may move between them:
    1. HBeAg-positive chronic infection (Immune tolerant phase): High HBV DNA (>1,000,000 IU/mL), positive HBeAg, normal ALT, minimal liver inflammation/fibrosis. Often seen in individuals infected perinatally or in early childhood.
    2. HBeAg-positive chronic hepatitis (Immune active phase): High HBV DNA (>20,000 IU/mL), positive HBeAg, elevated ALT, significant liver inflammation/fibrosis.
    3. HBeAg-negative chronic infection (Inactive carrier phase): Low or undetectable HBV DNA (<2,000 IU/mL), negative HBeAg, positive anti-HBe, normal ALT, minimal liver inflammation/fibrosis. Represents the majority of chronic HBV patients in low-endemic areas.
    4. HBeAg-negative chronic hepatitis (Immune active phase): Low to moderate HBV DNA (typically >2,000 IU/mL, but can be higher), negative HBeAg, positive anti-HBe, elevated ALT, significant liver inflammation/fibrosis. Often due to HBV pre-core or basal core promoter mutations.
    5. HBsAg-negative phase (Occult HBV infection): HBsAg is undetectable, but HBV DNA may be detectable in liver tissue or serum (often at very low levels). Anti-HBc (and sometimes anti-HBs) may be present. This phase is less common and can reactivate under immunosuppression.

Pathophysiology

• Mechanism:
  • Viral Structure: HBV is a partially double-stranded DNA virus. It contains four open reading frames (ORFs) encoding for envelope proteins (HBsAg), core proteins (HBcAg, HBeAg), polymerase, and X protein.
  • Replication Cycle: HBV enters hepatocytes and delivers its partially double-stranded DNA genome to the nucleus, where it is repaired to form covalently closed circular DNA (cccDNA). cccDNA acts as the template for transcription of viral mRNAs, which are then translated into viral proteins or reverse-transcribed by the viral polymerase into new viral DNA genomes. These can then be packaged into virions or returned to the nucleus to replenish the cccDNA pool. cccDNA is highly stable, making HBV eradication challenging.
  • Immune Response and Liver Damage: Liver injury in HBV infection is primarily immune-mediated, not directly cytopathic. The host's cytotoxic T-lymphocytes (CTLs) target HBV-infected hepatocytes.
    • Acute HBV: A strong, multi-specific CTL response rapidly clears infected cells, leading to viral eradication and resolution of infection. Liver inflammation and hepatocellular necrosis result from this immune attack.
    • Chronic HBV: A weak, narrowly focused, or exhausted CTL response allows HBV to persist. Sustained immune activity against infected hepatocytes leads to chronic inflammation, fibrosis, and eventual development of cirrhosis and HCC. HBeAg plays a role in modulating the immune response, promoting immune tolerance in early infection.
• Risk Factors:
  • Perinatal transmission: Mother HBeAg positive, high HBV DNA levels.
  • Sexual contact: Unprotected sex, multiple partners, history of sexually transmitted infections (STIs).
  • Injection drug use: Sharing needles or drug paraphernalia.
  • Unsafe healthcare practices: Reuse of needles, unsterilized medical/dental equipment, inadequate infection control.
  • Tattooing and body piercing: Using unsterile equipment.
  • Blood transfusions: Prior to universal screening, a significant risk. Now very low risk in countries with rigorous screening.
  • Household contact: Living with an HBV-infected person, particularly sharing razors, toothbrushes.
  • Immigration from endemic areas: Being born or raised in regions with high HBV prevalence.
  • Hemodialysis: Increased risk due to exposure to blood and shared equipment.
  • Immunosuppression: Increased risk of reactivation of occult or chronic HBV infection.
• Protective Factors:
  • Vaccination: Universal infant vaccination and vaccination of at-risk adults is the most effective primary prevention strategy.
  • Safe injection practices: Avoid sharing needles, using sterile equipment in healthcare settings.
  • Safe sexual practices: Condom use, limiting sexual partners.
  • Screening of blood products: Mandatory screening of blood donations for HBsAg.
  • Maternal screening and prevention: Screening of all pregnant women for HBsAg and administration of HBIG and HBV vaccine to infants of HBsAg-positive mothers within 12 hours of birth.
  • Post-exposure prophylaxis (PEP): Administration of HBIG and HBV vaccine following exposure to HBV.

Clinical Presentation

Signs and Symptoms

Acute HBV infection is often asymptomatic, especially in children. When symptoms occur, they typically appear 60-150 days (average 90 days) after exposure.

• Cardinal Features (when symptomatic):
  • Fatigue: Profound and persistent.
  • Nausea/Vomiting: Loss of appetite, abdominal discomfort.
  • Jaundice: Yellowing of skin and sclera (occurs in <10% of infected children and 30-50% of infected adults).
  • Dark urine: Due to bilirubinuria.
  • Pale stools: Due to impaired bile flow.
  • Right upper quadrant (RUQ) pain: Due to liver inflammation.
• Early Signs (Prodromal):
  • Malaise, anorexia, fatigue
  • Nausea, vomiting, abdominal discomfort
  • Myalgia, arthralgia
  • Headache
  • Low-grade fever
  • Urticarial rash (less common)
• Advanced Signs (Chronic HBV and Complications):
  • Cirrhosis: Ascites (fluid in abdomen), peripheral edema, spider angiomata, palmar erythema, muscle wasting, easy bruising, jaundice.
  • Hepatic encephalopathy: Confusion, altered mental status, asterixis (flapping tremor).
  • Variceal bleeding: Hematemesis, melena (due to portal hypertension).
  • Hepatocellular Carcinoma (HCC): Unexplained weight loss, new or worsening RUQ pain, palpable liver mass, sudden decompensation of liver function.
• Atypical Presentations:
  • Fulminant Hepatic Failure (FHF): Rare but life-threatening (0.1-0.5% of acute HBV cases). Rapid onset of severe liver dysfunction within 8 weeks of symptom onset, characterized by hepatic encephalopathy and coagulopathy (INR >1.5) in a patient with no pre-existing liver disease. Symptoms may include profound fatigue, severe nausea/vomiting, rapidly worsening jaundice, mental status changes.
  • Extrahepatic Manifestations: Less common but can include polyarteritis nodosa, glomerulonephritis, essential mixed cryoglobulinemia, papular acrodermatitis of childhood (Gianotti-Crosti syndrome).

Physical Examination

Findings depend on the stage of infection.

• Inspection:
  • Acute Hepatitis: Jaundice of skin and sclera, dark urine (if observed).
  • Chronic Liver Disease/Cirrhosis:
    • Skin: Jaundice, spider angiomata (upper body), palmar erythema, caput medusae (dilated periumbilical veins).
    • Extremities: Peripheral edema, clubbing, muscle wasting.
    • Abdomen: Ascites (distension, bulging flanks), umbilical hernia.
    • General: Cachexia, altered mental status (encephalopathy).
• Palpation:
  • Acute Hepatitis: Hepatomegaly (enlarged liver) with tenderness in the RUQ.
  • Chronic Liver Disease/Cirrhosis:
    • Liver: May be enlarged, firm, or nodular. In advanced cirrhosis, liver size may shrink. Tenderness may or may not be present.
    • Spleen: Splenomegaly (enlarged spleen) due to portal hypertension.
    • Abdomen: Shifting dullness, fluid wave (for ascites).
• Special Tests:
  • No "special tests" specific to HBV on physical exam beyond general liver disease assessments.
  • Assessment for signs of hepatic encephalopathy (e.g., asterixis).
  • Percussion for liver span and splenic size.

Diagnostic Approach

History Taking

• Key Questions:
  • Risk Factors:
    • Country of birth and origin of parents (especially if from HBV-endemic regions).
    • Family history of liver disease, HBV, or HCC.
    • Sexual history (number of partners, history of STIs, unprotected sex).
    • History of injection drug use, tattooing, body piercing.
    • History of blood transfusions (especially pre-1992 in many countries).
    • Occupational exposure (healthcare workers).
    • Household contact with known HBV-infected individuals.
    • History of incarceration.
    • Travel history to HBV-endemic areas.
  • Symptoms: Onset, duration, and severity of fatigue, nausea, vomiting, abdominal pain, jaundice, dark urine, pale stools, unexplained weight loss.
  • Past Medical History: History of other liver diseases, HIV, HCV, autoimmune conditions, kidney disease, immunosuppression.
  • Medications: Current medications, herbal supplements, alcohol use.
  • Vaccination Status: History of HBV vaccination.
• Red Flags:
  • Rapid onset of jaundice, encephalopathy, and coagulopathy (INR >1.5) in acute infection (suggests fulminant hepatic failure).
  • New or worsening ascites, peripheral edema, variceal bleeding, or encephalopathy in a patient with chronic HBV (suggests decompensated cirrhosis).
  • Unexplained weight loss, new-onset RUQ pain, or rapid deterioration of liver function in chronic HBV (suggests HCC).

Laboratory Tests

Understanding HBV serology is crucial for diagnosis and staging.

• First-Line Diagnostic Tests (Initial Screening Panel):
  • Hepatitis B Surface Antigen (HBsAg): The presence of HBsAg indicates active HBV infection (acute or chronic). If positive for ≥6 months, it indicates chronic HBV.
  • Hepatitis B Surface Antibody (anti-HBs or HBsAb): Indicates immunity to HBV, either from successful vaccination or resolved infection.
  • Total Hepatitis B Core Antibody (anti-HBc or HBcAb, total): Indicates past or present infection. It appears early in infection and persists for life.
  • IgM Hepatitis B Core Antibody (IgM anti-HBc): Indicates acute or recent HBV infection (usually present for 4-6 months, can persist longer in some acute infections or flare-ups of chronic infection).
  • Interpretation Key (Simplified):
    • Susceptible: HBsAg (-), anti-HBs (-), anti-HBc (-)
    • Immune due to vaccination: HBsAg (-), anti-HBs (+), anti-HBc (-)
    • Immune due to natural infection: HBsAg (-), anti-HBs (+), anti-HBc (+)
    • Acute infection: HBsAg (+), IgM anti-HBc (+), anti-HBs (-)
    • Chronic infection: HBsAg (+), IgM anti-HBc (-), anti-HBs (-) (or sometimes low levels of anti-HBs are detected)
    • Resolved infection (immune): HBsAg (-), anti-HBs (+), anti-HBc (+)
    • Occult HBV or False Positive: HBsAg (-), anti-HBs (-), anti-HBc (+) (requires further investigation, e.g., HBV DNA)
• Confirmatory and Staging Tests:
  • Hepatitis B e-Antigen (HBeAg): Indicates active viral replication and high infectivity.
  • Hepatitis B e-Antibody (anti-HBe or HBeAb): Indicates seroconversion from HBeAg, typically associated with lower viral replication and reduced infectivity (inactive carrier state or HBeAg-negative CHB).
  • HBV DNA (viral load) by PCR: Quantifies the amount of HBV in the blood. Crucial for assessing viral replication, monitoring treatment response, and guiding management decisions.
    • Reference ranges for treatment initiation: Typically >20,000 IU/mL for HBeAg-positive CHB, and >2,000 IU/mL for HBeAg-negative CHB.
  • Liver Function Tests (LFTs): ALT, AST, alkaline phosphatase, GGT, bilirubin (total and direct). Elevated ALT/AST indicate hepatocyte inflammation/damage.
  • Liver Synthetic Function: Albumin, INR/PT (prothrombin time). Reflect liver's ability to synthesize proteins. Abnormal levels indicate severe liver dysfunction.
• Monitoring Tests (for Chronic HBV):
  • Regular LFTs (ALT/AST): Every 3-6 months.
  • HBV DNA: Every 3-6 months initially, then every 6-12 months for stable patients or those on treatment.
  • HBsAg quantification: May predict HBsAg seroclearance, but not routinely used for treatment initiation. Can be used as a marker for response to Peg-IFN.
  • HBeAg and anti-HBe: Every 6-12 months for HBeAg-positive patients, to monitor for HBeAg seroconversion.
  • Alpha-Fetoprotein (AFP): A tumor marker, used every 6 months for HCC surveillance in high-risk patients.
  • Fibrosis Markers: Non-invasive tests like FIB-4 score, APRI score, or FibroScan.

Imaging

• Recommended Imaging (for Chronic HBV):
  • Abdominal Ultrasound (US):
    • Purpose: Initial assessment of liver morphology, presence of cirrhosis (nodularity, portal hypertension signs), splenomegaly, and most importantly, surveillance for hepatocellular carcinoma (HCC).
    • Frequency: Every 6 months for high-risk patients (e.g., those with cirrhosis, family history of HCC, African descent males >40, Asian descent males >40, Asian descent females >50, any patient with CHB and significant fibrosis (F3-F4)).
• Advanced Imaging (When Needed):
  • Transient Elastography (FibroScan):
    • Purpose: Non-invasive assessment of liver stiffness, which correlates with the degree of liver fibrosis/cirrhosis. It helps guide treatment decisions and prognosis.
    • Values: Typically, a liver stiffness measurement >11-12 kPa indicates cirrhosis (F4). Specific cut-offs vary based on etiology and device.
  • Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) of the Abdomen:
    • Purpose: To further characterize focal liver lesions detected on ultrasound, stage HCC, or evaluate for portal hypertension complications. Often performed with multiphasic contrast for optimal lesion characterization.
  • Liver Biopsy:
    • Purpose: Gold standard for assessing liver inflammation and fibrosis, especially when non-invasive tests are equivocal or other diagnoses are considered. Less commonly performed now given advancements in non-invasive tests and clear treatment guidelines.

Management

Acute Management

Acute HBV infection is typically self-limited, and treatment is primarily supportive. - Immediate: - Rest and adequate hydration. - Avoidance of hepatotoxic substances (e.g., alcohol, acetaminophen in large doses, certain herbal remedies). - Review and adjust medications that may be metabolized by the liver. - Stabilization: - Close monitoring of LFTs (ALT, AST, bilirubin), INR, and mental status. - For patients with severe acute hepatitis (prolonged INR, signs of encephalopathy, or declining synthetic function), hospitalization is warranted. - Antiviral therapy (e.g., nucleos(t)ide analogs like entecavir or tenofovir) may be considered for severe acute hepatitis, especially if there's evidence of impending liver failure or risk of progression, though the evidence for benefit is not as strong as for chronic HBV. - Emergency (Fulminant Hepatic Failure): - Urgent referral to a liver transplant center. - Intensive care unit (ICU) management for complications like hepatic encephalopathy, coagulopathy, cerebral edema, renal failure, and sepsis. - Consider early initiation of antiviral therapy (e.g., entecavir 0.5 mg daily or tenofovir disoproxil fumarate (TDF) 300 mg daily or tenofovir alafenamide (TAF) 25 mg daily) as a bridge to transplant or in the hope of avoiding it, though the primary intervention is often transplantation.

Chronic Management

The goal of chronic HBV management is to prevent progression to cirrhosis, liver failure, and HCC by achieving sustained suppression of HBV replication. Not all patients with chronic HBV require immediate antiviral therapy.

• Pharmacological:
  • Nucleos(t)ide Analogs (NUCs): Highly potent and generally well-tolerated oral antivirals that suppress HBV replication.
    • First-line Agents (High potency, high barrier to resistance):
      • Entecavir (ETV):
        • Dosage: 0.5 mg orally once daily for treatment-naïve patients; 1 mg orally once daily for lamivudine-refractory patients. Dosing adjustments for renal impairment are crucial.
        • Mechanism: Guanosine analog that inhibits HBV DNA polymerase.
        • Adverse Effects: Generally well-tolerated. Lactic acidosis (rare but serious), headache, fatigue, dizziness, nausea.
      • Tenofovir Disoproxil Fumarate (TDF):
        • Dosage: 300 mg orally once daily. Dosing adjustments for renal impairment are crucial.
        • Mechanism: Acyclic nucleotide analog that inhibits HBV reverse transcriptase.
        • Adverse Effects: Generally well-tolerated. Potential for renal toxicity (creatinine elevation, hypophosphatemia, Fanconi syndrome) and bone mineral density loss.
      • Tenofovir Alafenamide (TAF):
        • Dosage: 25 mg orally once daily. Minimal renal dose adjustment required (CrCl 15- <30 mL/min for dialysis patients, not recommended if CrCl <15 mL/min without dialysis).
        • Mechanism: Prodrug of tenofovir, delivers tenofovir to hepatocytes more efficiently, allowing for a lower dose and less systemic exposure.
        • Adverse Effects: Improved renal and bone safety profile compared to TDF. Potential for weight gain, lipid changes.
    • Other NUCs (Less Preferred Due to Resistance/Potency):
      • Lamivudine (high resistance rates, generally not used as monotherapy)
      • Adefovir dipivoxil (lower potency, higher renal toxicity than TDF)
      • Telbivudine (moderate potency, risk of myopathy and peripheral neuropathy)
  • Pegylated Interferon Alpha (Peg-IFNα):
    • Dosage: Peg-IFNα-2a 180 mcg subcutaneously once weekly for 48 weeks.
    • Mechanism: Immunomodulatory, antiviral effects, induces HBeAg seroconversion and HBsAg loss in some patients.
    • Adverse Effects: Flu-like symptoms (fever, fatigue, myalgia), depression, cytopenias, thyroid dysfunction, autoimmune exacerbations.
    • Considerations: Not for patients with decompensated cirrhosis. Often reserved for younger patients without advanced fibrosis or specific indications, and for those who desire a finite course of treatment.
• Non-pharmacological:
  • Alcohol Avoidance: Strictly avoid alcohol, as it exacerbates liver damage.
  • Healthy Lifestyle: Maintain a healthy diet, exercise regularly, and manage body weight to prevent non-alcoholic fatty liver disease (NAFLD), which can further worsen liver function.
  • Vaccinations: Ensure vaccination for Hepatitis A virus (HAV) and Hepatitis C virus (HCV) if not immune, to prevent co-infections that can accelerate liver disease.
  • Avoidance of Hepatotoxins: Avoid unnecessary medications or herbal supplements known to be hepatotoxic.
• Monitoring (Long-term follow-up):
  • Clinical Assessment: Regular visits (every 3-12 months depending on disease activity and treatment status) to assess symptoms, physical exam for signs of liver decompensation.
  • Laboratory Tests:
    • LFTs (ALT/AST, bilirubin, albumin, INR): Every 3-6 months.
    • HBV DNA: Every 3-6 months when initiating or changing treatment, then every 6-12 months for stable patients.
    • HBeAg/anti-HBe: Every 6-12 months for HBeAg-positive patients until seroconversion.
    • HBsAg quantification: May be monitored, especially for patients on Peg-IFN or those with an aim for HBsAg loss.
    • Renal function (creatinine, eGFR, phosphate): Every 3-12 months, especially for patients on TDF.
    • HCC Surveillance: Abdominal ultrasound + AFP every 6 months for high-risk patients.

Treatment Algorithms

Treatment decisions are complex and guided by HBV phase, ALT levels, HBV DNA levels, and degree of liver fibrosis/cirrhosis.

• Indications for Antiviral Treatment (General Guidelines - AASLD/EASL):
  • Cirrhosis (compensated or decompensated): All patients with CHB and cirrhosis should be treated, regardless of HBeAg status, ALT, or HBV DNA levels.
  • HBeAg-positive chronic hepatitis (Immune active):
    • HBV DNA >20,000 IU/mL (5 log10 copies/mL) AND
    • ALT persistently elevated (>2x ULN) AND/OR
    • Evidence of significant liver inflammation or fibrosis (e.g., biopsy showing moderate-severe inflammation or fibrosis F2-F4, or FibroScan >7-9 kPa).
  • HBeAg-negative chronic hepatitis (Immune active):
    • HBV DNA >2,000 IU/mL (3 log10 copies/mL) AND
    • ALT persistently elevated (>2x ULN) AND/OR
    • Evidence of significant liver inflammation or fibrosis.
  • Immune Tolerant Phase: Treatment generally not recommended. However, consider if:
    • Patients >30-40 years with persistently normal ALT, high HBV DNA, but significant fibrosis (F2 or higher by biopsy/elastography).
    • Family history of HCC or cirrhosis.
  • HBsAg-negative phase (occult HBV): Antiviral prophylaxis is indicated if severe immunosuppression (e.g., chemotherapy, rituximab, transplant).
• First-Line Treatment Approach:
  • Preferred Agents: Oral NUCs: Entecavir, Tenofovir Disoproxil Fumarate (TDF), or Tenofovir Alafenamide (TAF). These are generally preferred due to high potency, high barrier to resistance, and good safety profiles for long-term use.
  • Pegylated Interferon (Peg-IFN): May be considered for carefully selected patients, particularly those with HBeAg-positive CHB, higher ALT, and desire for a finite course of treatment with a chance of HBsAg seroclearance. Not for patients with decompensated cirrhosis.
• Second-Line Treatment Approach:
  • Generally involves switching to another first-line NUC if the initial therapy is ineffective, poorly tolerated, or if resistance develops.
  • Management of NUC Resistance: If resistance to one NUC develops (e.g., lamivudine), switch to or add a high-barrier-to-resistance NUC (e.g., TDF/TAF or ETV, ensuring no cross-resistance). For ETV resistance, switch to TDF/TAF. For TDF resistance (rare), switch to ETV or a combination.
• Refractory Cases:
  • Non-response: Defined as <1 log10 IU/mL decrease in HBV DNA after 6-12 months of treatment, or persistently detectable HBV DNA despite adequate adherence.
  • Partial response: Detectable HBV DNA but >1 log10 IU/mL decrease from baseline.
  • Management:
    • Confirm adherence to medication.
    • Assess for resistance mutations (genotyping).
    • Switch to an alternative NUC with a high barrier to resistance and no cross-resistance to the previous agent (e.g., TAF or TDF for ETV resistance, or vice versa).
    • Combination therapy is rarely necessary except in cases of multidrug resistance, often guided by expert opinion and resistance testing.

Complications

• Common:
  • Cirrhosis: Persistent inflammation and fibrosis of the liver leading to architectural distortion and impaired function.
  • Hepatocellular Carcinoma (HCC): HBV is a major risk factor for HCC, even in the absence of cirrhosis. Integration of viral DNA into the host genome and chronic inflammation are implicated.
• Serious:
  • Decompensated Cirrhosis: Manifestations include:
    • Ascites: Accumulation of fluid in the peritoneal cavity.
    • Esophageal/Gastric Varices and Bleeding: Dilated blood vessels in the esophagus or stomach due to portal hypertension, prone to rupture and severe hemorrhage.
    • Hepatic Encephalopathy: Neuropsychiatric abnormalities due to liver failure and accumulation of toxins.
    • Spontaneous Bacterial Peritonitis (SBP): Infection of ascitic fluid without an obvious source.
    • Hepatorenal Syndrome: Renal failure in the setting of advanced liver disease.
  • Fulminant Hepatic Failure: Rapidly progressing liver failure with severe coagulopathy and encephalopathy, often requiring emergency liver transplant.
• Long-term:
  • Renal Impairment: Particularly with long-term TDF use, can lead to chronic kidney disease, Fanconi syndrome, and electrolyte abnormalities (hypophosphatemia). TAF has a better renal safety profile.
  • Bone Mineral Density Loss: TDF use is associated with a decrease in bone mineral density, increasing the risk of osteoporosis and fractures. TAF has a better bone safety profile.
  • Extrahepatic Manifestations: Polyarteritis nodosa, glomerulonephritis, essential mixed cryoglobulinemia (less common).

Prognosis

• Factors Affecting Outcome:
  • Host Factors: Age at infection (earlier infection = higher chronicity risk), gender (males higher risk of progression), ethnicity (Asian and African populations have higher risk), genetic factors, alcohol consumption, co-infection with HIV/HCV/HDV.
  • Viral Factors: HBV DNA levels (higher viral load = worse prognosis), HBeAg status (HBeAg-positive generally worse if untreated), HBV genotype (some genotypes linked to more aggressive disease/HCC risk).
  • Disease Stage: Presence of cirrhosis is the strongest predictor of progression to decompensation and HCC.
  • Treatment Response: Achieving and maintaining viral suppression significantly improves prognosis.
• Survival:
  • Acute HBV: Prognosis is generally excellent with full recovery in >95% of adults. Fulminant hepatitis is rare but has a high mortality rate (70-80% without transplant).
  • Chronic HBV: Variable.
    • Untreated chronic HBV: Approximately 15-40% of patients develop cirrhosis over their lifetime, with an annual risk of decompensation of 3-5% for those with compensated cirrhosis, and an annual risk of HCC of 2-5% for those with cirrhosis.
    • Treated chronic HBV: Antiviral therapy significantly reduces the risk of cirrhosis progression, decompensation, and HCC, leading to improved survival rates. HBsAg seroclearance (functional cure) is associated with an excellent long-term prognosis, approaching that of the general population.
• Quality of Life: Chronic HBV can significantly impact quality of life due to chronic fatigue, anxiety, fear of progression, and side effects of medication. Successful treatment and viral suppression can improve physical and mental well-being, but the need for long-term monitoring and potential for complications remain.

Prevention

• Primary Prevention: Preventing initial HBV infection.
  • Hepatitis B Vaccination:
    • Universal Infant Vaccination: All neonates should receive the first dose of HBV vaccine at birth, followed by a complete series (typically 3 doses: 0, 1-2, 6 months).
    • Catch-up Vaccination: All unvaccinated children and adolescents <19 years.
    • Adult Vaccination: Recommended for all susceptible adults at risk of infection (e.g., healthcare workers, injection drug users, MSM, multiple sexual partners, household/sexual contacts of HBsAg-positive persons, persons from HBV-endemic areas, chronic liver disease, end-stage renal disease).
    • Vaccine Series: Standard 3-dose regimen (e.g., Engerix-B, Recombivax HB). Newer 2-dose regimen (Heplisav-B) for adults ≥18 years.
    • Post-vaccination testing: Anti-HBs testing 1-2 months after the last dose for healthcare workers, infants of HBsAg-positive mothers, and immunocompromised individuals, to confirm seroprotection (anti-HBs >10 mIU/mL).
  • Maternal Screening and Perinatal Prophylaxis:
    • All pregnant women should be screened for HBsAg.
    • Infants born to HBsAg-positive mothers should receive Hepatitis B Immune Globulin (HBIG, 0.5 mL IM) and the first dose of HBV vaccine within 12 hours of birth. The vaccine series should be completed according to schedule.
    • Antiviral therapy (typically TDF) may be given to HBsAg-positive mothers with high HBV DNA levels (>200,000 IU/mL or 6 log10 IU/mL) during the third trimester to reduce perinatal transmission risk.
  • Blood Safety: Screening of all donated blood for HBsAg.
  • Safe Injection Practices: Universal precautions in healthcare settings, safe needle disposal, harm reduction programs for injection drug users.
  • Safe Sexual Practices: Consistent and correct condom use, limiting sexual partners.
  • Post-Exposure Prophylaxis (PEP): Administration of HBIG and HBV vaccine after percutaneous or mucosal exposure to HBV-infected blood, or sexual exposure.
• Secondary Prevention: Early detection and intervention to prevent disease progression.
  • Screening: Targeted screening of high-risk populations for chronic HBV.
  • Antiviral Therapy: Initiating antiviral therapy in appropriate patients to suppress viral replication and prevent progression to cirrhosis and HCC.
• Tertiary Prevention: Preventing complications in those with established chronic HBV.
  • HCC Surveillance: Regular (every 6 months) abdominal ultrasound +/- AFP for high-risk patients.
  • Management of Cirrhosis Complications: Prophylactic beta-blockers for varices, diuretics for ascites, lactulose for encephalopathy, surveillance for SBP, and early referral for liver transplant when indicated.

Special Populations

• Pediatric:
  • Perinatal Transmission: Most common route in endemic areas. Prevention with HBIG + vaccine at birth is paramount.
  • Chronic Infection: Children infected perinatally often enter an "immune tolerant" phase with high HBV DNA, normal ALT, and minimal liver disease. Treatment in this phase is generally deferred unless there is evidence of active liver disease (elevated ALT, significant fibrosis).
  • Treatment: Entecavir and TDF are approved for children aged ≥2 years, TAF ≥12 years. Dosing is weight-based. Peg-IFN is an option for certain pediatric patients.
• Geriatric:
  • Comorbidities: Higher prevalence of comorbidities (renal impairment, cardiovascular disease, diabetes) influencing drug choice (e.g., TAF preferred over TDF for renal safety).
  • Immunosenescence: May have altered immune response and potentially different disease progression patterns.
  • Polypharmacy: Increased risk of drug-drug interactions with antiviral medications.
• Pregnancy:
  • Screening: All pregnant women should be screened for HBsAg.
  • Antiviral Therapy: Antiviral therapy (TDF is preferred due to excellent safety profile in pregnancy) for HBsAg-positive mothers with high HBV DNA (>200,000 IU/mL or 6 log10 IU/mL) initiated in the late second or early third trimester (e.g., Week 28-32) to reduce the risk of perinatal transmission. It can be discontinued soon after delivery, but the risk of flare needs to be monitored.
  • Breastfeeding: TDF and ETV are considered safe for breastfeeding.
• Comorbidities:
  • HIV Co-infection: All HIV-infected individuals should be screened for HBV. If co-infected, HBV treatment should cover both viruses (e.g., using TDF/TAF-containing regimens). Co-infection often leads to more rapid progression of liver disease.
  • HCV Co-infection: May accelerate liver disease progression. Treatment for both viruses is typically managed sequentially or concurrently based on guidelines.
  • Renal Impairment: Careful dose adjustment for NUCs (especially ETV and TDF) is critical. TAF has a more favorable renal safety profile.
  • Immunosuppression: Patients requiring immunosuppressive therapy (e.g., chemotherapy, biologics like rituximab, organ transplantation) are at high risk of HBV reactivation. All HBsAg-positive and anti-HBc positive (even HBsAg-negative) patients should be screened before starting immunosuppression and receive prophylactic antiviral therapy if needed.

Clinical Pearls

• Diagnostic:
  • Serology is key: A thorough understanding of HBsAg, anti-HBs, anti-HBc (total and IgM) is fundamental for accurate diagnosis and staging. Don't just order "Hepatitis B Panel," understand each component.
  • HBsAg persistence > 6 months: Defines chronic HBV infection.
  • "Immune window": During acute infection, HBsAg may clear before anti-HBs appears. In this phase, IgM anti-HBc is the only positive marker.
  • Occult HBV: HBsAg negative, but anti-HBc positive (and sometimes anti-HBs positive) with detectable HBV DNA. Important in immunocompromised patients.
• Treatment:
  • Not all chronic HBV patients need immediate treatment: The decision to treat is based on HBV DNA, ALT, HBeAg status, and especially the presence of significant fibrosis or cirrhosis.
  • NUCs are generally lifelong: Unlike HCV, HBV functional cure (HBsAg loss) is rare. NUCs typically need to be continued indefinitely, especially in cirrhotic patients, to prevent viral rebound and disease progression.
  • Regular monitoring is critical: For viral suppression, liver function, renal function, bone health (with TDF), and HCC surveillance.
  • Educate patients: Emphasize adherence, safe practices, and the importance of long-term follow-up.
• Pitfalls:
  • Missing HCC: Inadequate or absent HCC surveillance in high-risk patients.
  • Misinterpreting serology: Leading to incorrect diagnosis of acute vs. chronic, or immune vs. susceptible status.
  • Inappropriate treatment initiation/cessation: Treating patients in the immune tolerant phase unnecessarily, or stopping NUCs too early, leading to flares.
  • Neglecting renal/bone health: Especially with TDF, failing to monitor creatinine, eGFR, phosphate, and consider TAF for those at risk.
  • Lack of pre-immunosuppression screening: Leading to potentially life-threatening HBV reactivation.

Recent Updates

• Guidelines: Current management guidelines are predominantly from the American Association for the Study of Liver Diseases (AASLD) (updated 2018), European Association for the Study of the Liver (EASL) (updated 2019), and World Health Organization (WHO) (updated 2015, with ongoing updates).
• Evidence:
  • Tenofovir Alafenamide (TAF): Strong evidence supporting its efficacy and improved renal and bone safety profile compared to TDF, making it a preferred first-line NUC, particularly in patients with pre-existing renal disease, risk factors for bone disease, or older age.
  • HBsAg quantification: Growing evidence for its utility in predicting HBsAg seroclearance and guiding Peg-IFN therapy, though not yet a primary driver for NUC treatment initiation.
  • Treatment Cessation: Research continues on safe NUC cessation strategies for HBeAg-negative patients with sustained viral suppression, but this remains a complex area and not routinely recommended for most patients outside of clinical trials. HBsAg loss is generally required.
• Controversies:
  • Treatment of Immune Tolerant Phase: Debate continues on whether to treat older patients (>30-40 years) in the immune tolerant phase who have normal ALT but evidence of significant fibrosis (e.g., F2-F3). Some guidelines now recommend considering treatment in these cases.
  • Duration of NUC Therapy: For most patients, NUCs are lifelong. However, the search for finite treatment regimens and predictors for safe NUC discontinuation (especially in HBeAg-negative patients) is an active area of research.
  • Role of Immune Modulators: Development of new immune-modulating agents and therapies targeting cccDNA to achieve a "functional cure" (HBsAg loss) is a major focus in HBV research.

Key References

• Guidelines:
  • Terrault NA, et al. AASLD guidelines for treatment of chronic hepatitis B: Update 2018. Hepatology. 2018;67(4):1560-1599.
  • European Association for the Study of the Liver. EASL 2019 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2019;70(2):321-369.
  • World Health Organization (WHO) guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015. (Updates ongoing and available through WHO website).
  • Centers for Disease Control and Prevention (CDC) - Viral Hepatitis.
• Studies:
  • Numerous pivotal trials for entecavir (e.g., P.K. Lai et al.), tenofovir disoproxil fumarate (e.g., S.F. Fung et al.), and tenofovir alafenamide (e.g., M.P.खिल-P.M. Pan et al.), establishing their efficacy and safety.
• Reviews:
  • Comprehensive reviews on HBV management in leading gastroenterology/hepatology journals (e.g., Gastroenterology, Hepatology, Journal of Hepatology) and clinical reference databases (e.g., UpToDate, Harrison's Principles of Internal Medicine).